Susquehanna Fundamental Investments, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$27.21 - $39.48 $3.49 Million - $5.06 Million	128,083 New	128,083 $3.66 Billion
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $864,988 - $1.41 Million	-29,193 Reduced 61.73%	18,100 $598,000
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $717,122 - $1.27 Million	18,100 Added 62.0%	47,293 $2.18 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $546,162 - $775,759	-9,402 Reduced 24.36%	29,193 $1.94 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $1.27 Million - $1.84 Million	21,698 Added 128.41%	38,595 $2.41 Million
Q2 2021 Aug 11, 2021	BUY	$62.15 - $90.32 $1.05 Million - $1.53 Million	16,897 New	16,897 $1.4 Million

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.